7514. Pixantrone

Nomenclature

CAS number: 144510-96-3
6,9-Bis[(2-aminoethyl)amino]benz[g]isoquinoline-5,10-dione.
C17H19N5O2; mol wt 325.37.
C 62.75%, H 5.89%, N 21.52%, O 9.83%.

Description and references

Second generation aza-anthracenedione analog which intercalates DNA and inhibits topoisomerase II; structurally similar to mitoxantrone, q.v. Prepn: P. A. Krapcho, EP 503537 (1992 to Univ. of Vermont); idem et al., J. Med. Chem. 37, 828 (1994). Solid-state characterization: A. Marini et al., J. Pharm. Sci. 92, 577 (2003). Antitumor spectrum and evaluation of cardiotoxic potential: G. Beggiolin et al., Tumori 87, 407 (2001). Immunosuppressant activity: G. Cavaletti et al., J. Neuroimmunol. 151, 55 (2004). Clinical pharmacokinetics: S. Faivre et al., Clin. Cancer Res. 7, 43 (2001). Clinical evaluation in non-Hodgkin's lymphoma: P. Borchmann et al., Haematologica 88, 888 (2003). Review of development and therapeutic potential: P. Borchmann, R. Schnell, Expert Opin. Invest. Drugs 14, 1055-1061 (2005).

Chemical structure

Derivative

Dimalate salt.

Nomenclature

CAS number: 144675-97-8
BBR-2778.
C17H19N5O2.2C4H14O4; mol wt 577.67.
C 51.98%, H 8.20%, N 12.12%, O 27.70%.

Properties

Blue solid from ethanol and ether, mp 192° (dec). Moderately sol in physiological saline.

Derivative

Hydrochloride.

Nomenclature

CAS number: 175989-38-5
C17H19N5O2.HCl; mol wt 361.83.
C 56.43%, H 5.57%, N 19.36%, O 8.84%, Cl 9.80%.

Properties

Dark blue hygroscopic solid from chloroform, mp 209-212°.

Therapeutic Category

Antineoplastic.

Keywords

Antineoplastic; Topoisomerase II Inhibitor